Ratings Philogen S.p.A.

Equities

PHIL

IT0005373789

Real-time Borsa Italiana Other stock markets 10:55:41 2024-05-13 am EDT			5-day change	1st Jan Change
17.8 ^EUR	-1.11%		-0.84%	-3.78%

May. 07	Philogen, NFP and liquidity drop in first quarter	AN
Apr. 12	Indices up; Italy, industrial sales down	AN

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PHILOGEN S.P.A.	-3.78%	781M	-
VERTEX PHARMACEUTICALS INCORPORATED	+5.21%	109B	B+
REGENERON PHARMACEUTICALS, INC.	+11.55%	105B	B+
ARGENX SE	-0.06%	22.25B	B
BIONTECH SE	-12.17%	22.09B	B+
GENMAB A/S	-7.66%	18.68B	A-
WUXI APPTEC CO., LTD.	-36.52%	17.58B	A-
BEIGENE, LTD.	-9.79%	16.85B	B
NEUROCRINE BIOSCIENCES, INC.	+4.85%	13.76B	C+
SAREPTA THERAPEUTICS, INC.	+35.05%	12.46B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes